The operating cash flow breakeven milestone reduces near-term financing risk, but the company still has only $5.7M in cash against $17.5M in current debt maturities. Monitor the planned DrugSorb-ATR De Novo submission in early 2027 and progress on restoring Germany sales growth.
Drug in focus
CTSO drug pipeline →CytoSorb
▼ Bearish Named in this 8-K- Impact
- Phase
- Approved / Commercialized
- Time to market
- Already on the market (CE-marked in Europe, FDA-cleared in US)
- Next catalyst
- None dated
What to watchWatch the September 28, 2026 Nasdaq compliance deadline, if CTSO cannot sustain $1.00 for 10 consecutive trading days before then, delisting risk becomes acute. The DrugSorb-ATR FDA De Novo submission (submitted Q1 2026) is a potential positive catalyst but has no announced decision date. The stock is a high-risk micro-cap with limited cash runway and stagnant revenue.
Price Chart
Executive Summary
CytoSorbents reported Q3 2026 revenue of $9.7M (+3% YoY) and a net loss of $1.8M ($0.58/share), improving from a $3.2M loss in Q3 2025. The company achieved operating cash flow breakeven (excluding restructuring payments), a key milestone, while advancing DrugSorb-ATR toward a planned De Novo submission in early 2027.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $9.7M, up 3% from $9.5M in Q3 2025
- Gross margin improved to 75% from 70% a year ago
- Operating loss improved 59% to $1.2M from $2.9M
- Net loss improved 42% to $1.8M ($0.58/share) from $3.2M ($1.01/share)
- Generated positive operating cash flow of ~$43,000, excluding $251,000 restructuring payments
- Cash and equivalents $5.7M at Sept 30, 2026, down from $5.9M at June 30, 2026
- Planned DrugSorb-ATR De Novo submission in early 2027; real-world data showing 37% relative reduction in severe bleeding
- Germany sales declined 20% YoY, representing 24% of quarterly sales
- Distributor and strategic partner sales grew 18% YoY and 10% sequentially
Financial Impact
Revenue $9.7M, net loss $1.8M, operating cash flow ~$43K positive
Risk Factors
- Cash position of $5.7M is low relative to $17.5M in current debt maturities
- Germany sales declined 20% YoY; recovery depends on new sales hires becoming productive
- DrugSorb-ATR regulatory timeline subject to FDA review and potential delays
- Stockholders' deficit of $2.3M indicates negative equity position
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000929638-26-004267 |
| Document: a8k.htm | 0000929638-26-004267 |
| Document: 0000929638-26-004267-index-headers.html | 0000929638-26-004267 |
| Document: 0000929638-26-004267-index.html | 0000929638-26-004267 |
| Document: 0000929638-26-004267.txt | 0000929638-26-004267 |
| 8-K Data (Synthetic) | 0000929638-26-004267 |
Track record
12 reports on CTSO
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.94% at T+60 after the Aug 6, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 20, 20261d ago 424B5 Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
- Nov 20, 20261d ago 8-K Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
- Nov 19, 20263d ago 8-K/A Neutral 4/10 Entry $5.13 Now $4.16 −18.91% settles Feb 18
- Nov 17, 20265d ago NT 10-Q Neutral 4/10 Entry $4.52 Now $4.16 −7.96% settles Feb 16
- Nov 12, 20269d ago Press Release Neutral 4/10 Entry $4.87 Now $4.16 −14.58% settles Feb 11
- Nov 12, 20269d ago 8-K Neutral 5/10 Viewing No price data
- Sep 23, 20268w ago 8-K Mixed 5/10 Entry $4.91 Now $4.16 −15.27% settles Dec 17
- Aug 6, 202615w ago Press Release Bearish 6/10 Entry $0.3600 to $0.2270 Now $4.16 −1055.56% ▲ +36.94% +34.68% vs SPY
- Jun 25, 202621w ago DEFA14A Neutral 3/10 Entry $0.3620 to $0.2660 Now $4.16 +1049.17% ▼ −26.52% −32.61% vs SPY
- Jun 16, 202622w ago Insider Cluster Bullish 6/10 Entry $0.5189 to $0.3205 Now $4.16 +701.70% ▼ −38.23% −40.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers